

# IMAGE BASED BRACHYTHERAPY FOR CERVICAL CANCER



**DR. FIRUZA D.PATEL**  
**PROFESSOR**

**DEPARTMENT OF RADIOTHERAPY**  
**POSTGRADUATE INSTITUTE OF MEDICAL**  
**EDUCATION & RESEARCH, CHANDIGARH.**



# Image Based Brachytherapy

---

- ❑ Image guided brachytherapy
  - ❑ Technique where imaging is used to guide brachytherapy applicator/source placement.
  
- ❑ Image based brachytherapy
  - ❑ Technique where advanced imaging modalities are used to gain information regarding the volumetric dose distribution.



# Image Based Brachytherapy

---

- ❑ Historically
  - ❑ Dose prescription & treatment planning have been mainly based on traditional schools using a certain system, including a given technique, loading pattern, & dose rate.
  - ❑ “Manchester”, “Stockholm”, “Fletcher/MD Anderson”
  - ❑ Current practice is to prescribe dose to **Point A**
  - ❑ Empiric point, does not reflect dose to tumor, reference is with applicator, is located where **dose gradient is high i.e. about 10%/mm.**



# Image Based Brachytherapy

---

## ❑ Historically

- ❑ Uniform method for reporting **ICRU Report 38 (1985)**
- ❑ Dose be specified in terms of total reference air kerma TRAK
- ❑ Reference volume be determined – tissue **volume encompassed by a reference isodose surface, 60 Gy**
- ❑ **Points** for dose assessment **to bladder & rectum**
- ❑ Extended to dose-volume histograms DVH for OARs.
- ❑ Compare brachytherapy performed in different institutions.
- ❑ Applied only minimally, no correlation with primary cervical tumor control.



# Image Based Brachytherapy

---

- ❑ Recently
- ❑ **3D & 4D image–based brachytherapy** treatment planning & dosimetry has been used for Cancer Cervix.
- ❑ Prescribed dose is always **related to the target** while the actual coverage can be evaluated with the use of DVH parameters
- ❑ Shape the spatial dose to conform to the target volume
  - ❑ Reduce dose to normal tissues & hence reduce the normal tissue toxicity.
  - ❑ **Escalate dose to the tumor to produce greater rates of local control**



# Image Based Brachytherapy

---

- ❑ Imaging modalities used
  - ❑ Ultrasonography
  - ❑ Fluoroscopy
  - ❑ Computed tomography CT
    - ❑ 3D anatomic relationship of applicator & neighbouring structures
    - ❑ **Difficult to separate cervical tumor from uterus, rectum & bladder & to ascertain where cervix ends & vagina begins**
  - ❑ **MRI** T2-weighted images: High signal intensity,  
After ERT : intermediate signal intensity ( grey zones )
  - ❑ **PET**



# Image Based Brachytherapy

---


- ❑ Imaging modalities used
- ❑ MRI Scan
  - ❑ Superior soft tissue resolution & is **the best imaging modality for visualisation of cervical tumor size, volume & extent**
  - ❑ Distinction of tumor from normal uterus & cervix
  - ❑ Definition of parametrial, & vaginal infiltration of disease
  - ❑ Visualise the anatomic relationship between applicator & tumor & adequacy of radiation coverage
  - ❑ Doses to rectum & bladder can be assessed
  - ❑ **Multiplanar scanning capabilities**-coronal, sagittal & axial



# Image Based Brachytherapy



CT SCAN



MRI SCAN





# Image Based Brachytherapy

---

- ❑ Imaging modalities used
  - ❑ **MRI Scan – disadvantages**
    - ❑ **MRI – compatible applicator** made of nonferromagnetic materials. Titanium & zirconium alloy needles.
    - ❑ **Bony anatomy** not differentiated as well as on CT
    - ❑ **Treatment planning systems use Hounsfield numbers** hence they are not able to use MRI scans directly & it is necessary to fuse MRI with CT scans



# Image Based Brachytherapy

---

- ❑ Imaging modalities used
  
- ❑ **MRI Scan accuracy**
  - ❑ Tumor volume - 93%
  - ❑ Deep stromal invasion - 94%
  - ❑ Parametrial infiltration - 87-94%
  - ❑ Lymph node involvement - 72-93% similar to CT
  - ❑ Overall Staging - 76-89% better than CT,USG, Clinical



# Image Based Brachytherapy

---


## ❑ Requirements

- ❑ Imaging
- ❑ 'Image-able' & artifact free applicator
- ❑ Applicator fixation & immobilization
- ❑ Treatment planning system
- ❑ Compatible communication protocol-DICOM,so that the treatment planning system can interpret the images
- ❑ CT & MRI data sets need to be registered to superimpose one set on another
- ❑ Contouring tumor & OARs
- ❑ Dosimetry & dose-volume parameters for tumor & OARs



# Image Based Brachytherapy


- ❑ Tumor volume assessment
  - ❑ First based on **Clinical Examination**
  - ❑ Appropriate **documentation** in three dimensions
  - ❑ **Sectional imaging** gives information on tumor extension & configuration & its topography





# Image Based Brachytherapy

## TUMOUR EXTENSION AND PARAMETERS AT DIAGNOSIS





# Image Based Brachytherapy

**TUMOUR RESPONSE: GOOD**

	Volume	Width	Thickness	Height	Distance PSW right	Distance PSW left
<b>Diagnosis:</b> involvement of the right proximal parametrium	88 cm <sup>3</sup>	5 cm	5 cm	7 cm	4 cm	5 cm
<b>Brachytherapy:</b> minimal residual extension into the right parametrium	9 cm <sup>3</sup>	3 cm	2 cm	3 cm	5 cm	6 cm





# Image Based Brachytherapy

---


## □ Target Volume

### □ GTV

- Includes macroscopic tumor extension as detected by clinical examination (visualisation & palpation) & as visualised on MRI
- Change of GTVs during treatment –
  - At diagnosis **GTV<sub>D</sub>**
  - At brachytherapy **GTV<sub>B</sub>**



# Image Based Brachytherapy



The **GTV** encompasses the macroscopic tumour extension at time of brachytherapy:  
**high signal intensity mass(es)** (FSE, T2) in cervix/corpus, parametria, vagina, bladder and rectum





# Image Based Brachytherapy

---

## Target definition

### 2 CTVs

A first target related to the extent of GTV **at time of BT**:  
taking into account tumour extent at diagnosis.

#### □ High risk CTV

- Major risk of recurrence because of residual **macroscopic tumor**
- Intent is to deliver a total dose as high as possible to eradicate all ***residual macroscopic tumor***
- ***High dose prescribed to this target (80-90+ Gy) = dose to point A***



# Image Based Brachytherapy

---

## Target definition


### 2 CTVs

A second target related to the extent of GTV at diagnosis :

- ❑ **Intermediate risk CTV**
- ❑ Major risk of recurrence in areas that initially had macroscopic extent of disease with residual **microscopic** disease at time of BT
- ❑ Intent is to deliver dose appropriate to cure ***microscopic disease in cervix cancer***, which corresponds to a dose of **60Gy**





# Image Based Brachytherapy







# Image Based Brachytherapy



The HR-CTV includes **GTV**, **whole cervix**, and **presumed extracervical tumor extension**. Pathologic residual tissue(s) as defined by palpable indurations and/or **grey zones** in parametria, uterine corpus, vagina or rectum and bladder are included in HR-CTV. No safety margin are added



# Image Based Brachytherapy



HR-CTV + the initial tumour extension at diagnosis

**IR-CTV encompasses HR-CTV with a safety margin of 5-15 mm. Amount of safety margin is chosen according to tumour size an location, potential tumour spread, tumour regression and treatment strategy**




# Image Based Brachytherapy

---

- ❑ OARs
- ❑ Contouring organ wall volumes is difficult
- ❑ For organ wall volumes **upto 2-3 cm<sup>3</sup>, organ & organ wall contouring lead to almost identical numerical results** this allows for organ contouring only
- ❑ If larger organ wall volumes are considered organ wall contouring has to be performed
- ❑ When assessing the late effects from **brachytherapy, small organ (wall) volumes irradiated to a high dose seems to be of major interest.**



# Image Based Brachytherapy





# Image Based Brachytherapy




---

- ❑ Dose prescription
- ❑ **The prescribed dose is always related to the target.**
- ❑ **The prescription dose is the planned dose to cover this target as completely as possible.**
- ❑ Coverage of the target can be improved **starting from the standard dose prescription** & careful adaptation of the loading pattern & dwell times





# Image Based Brachytherapy



## ***Cervix Carcinoma***

Alain Gerbaulet, Richard Pötter, Christine Haie-Meder



# Image Based Brachytherapy

- ❑ **Dose prescription**
- ❑ **HR-CTV Dose**
  - ❑ Small tumor – **80-85 Gy**
  - ❑ Large tumor, good response – **85-90 Gy**
  - ❑ Large tumor, poor response – **90+ Gy**
- ❑ **IR-CTV ~ 60 Gy**
  
- ❑  **$V(60 \text{ Gy}_{\text{EQD}_2})$**  plays a role for evaluating the **IR CTV**
- ❑  **$V(85 \text{ Gy}_{\text{EQD}_2})$**  represents more closely the prescription dose to the **HR CTV**
  
- ❑ For comparison, dose reporting should refer to the prescribed dose to the image-based target **& to the traditional system - point A**



# Image Based Brachytherapy


---

- ❑ **Parameters for dosimetric evaluation GTV/CTV**
- ❑ **Prescribed Dose - PD**
- ❑ **D100 & D90** – minimum dose delivered to 100 & 90% of the volume of interest respectively
- ❑ D100 is extremely dependent on target delineation. Due to steep dose gradients, small spikes in the contour cause large deviations in D100
- ❑ **D90** is less sensitive to these influences & is therefore considered a more '**stable**' parameter
- ❑ **TRAK**
- ❑ **Point A Dose**
- ❑ **V 100** – Volume receiving  $\geq 100\%$  of PD
- ❑ **V150/200** – Volume receiving 150%/200% of PD



# Image Based Brachytherapy

- **Dose volume parameters**
- Coverage of target volumes can be derived from **cumulative DVH** analysis
- DVHs for GTV & CTV in I/C brachytherapy have a plateau-100% dose coverage of the volume of interest
- Plateau goes down smoothly indicating decreasing % of dose coverage with increasing dose



Potter, Radiat & Oncol, 78,2006



# Image Based Brachytherapy

---

## ❑ OARs


- ❑ As there is a rapid dose fall-off near the sources, in particular in adjacent small organ (wall) volumes, dose assessment has to refer to one (or more) defined dose points in these limited volumes
- ❑ **The minimum dose in the most irradiated tissue volume adjacent to the applicator ( $0.1, 1, 2, 5\text{cm}^3$ ) is recommended for recording & reporting**
- ❑ It is assumed that these **volumes are contiguous**
- ❑ This is **wrongly** called as the '**maximum dose**' to a  $2\text{cm}^3$  tissue



# Image Based Brachytherapy



**CLASSICAL MAX DOSE :** in 3D no clinical relevant endpoint

**FIXED VOLUME:** tolerance dose (total dose)-  
"minimum dose to the most exposed tissue"\*





# Image Based Brachytherapy



Potter, Radiat & Oncol, 78,2006



# Image Based Brachytherapy

---

## ❑ Dose volume constraints

- ❑ 2 cm<sup>3</sup> of rectum & sigmoid      **< 75 Gy<sub>3</sub>**
- ❑ 2 cm<sup>3</sup> of bladder      **< 90 Gy<sub>3</sub>**
- ❑ High risk CTV & D<sub>90</sub>      greater than the PD  
V<sub>100</sub> > 90%






# Image Based Brachytherapy

---

- ❑ Radiobiological modelling of doses:
  - ❑ **Standard brachytherapy dose-rate – 50cGy/hr**
  - ❑ Calculate the biologically weighted dose for brachytherapy
  - ❑ **Standard external beam radiotherapy is 200cGy/Fr**
  - ❑ Calculate the biologically weighted dose for external beam
  - ❑ **Add both together to get the Total Biologically weighted Dose for tumor & OAR**





# Image Based Brachytherapy





# Image Based Brachytherapy





# Image Based Brachytherapy

---

- Situations requiring combined I/C & I/S
  - Unilateral tumor extension exceeding
    - 3.5 cm at level of ring
    - 2.5 cm at level of pt A
    - 2.2 cm at a distance 3-4cm cranial to ring surface
  - Tumor extension cannot be covered by symmetrical dose distribution of tandem alone without exceeding dose limits for OAR
  - Tumor extension to lower vagina, close to pelvic side wall, posteriorly along ant rectal wall



# Image Based Brachytherapy

---

## BALANCE

3-D Image Based  
Dose volume relations  
in OAR : tolerable effects

3-D Image Based  
Dose volume relations  
in HR/IR CTV : control of disease



# Image Based Brachytherapy

---

## □ Conclusion

- It is expected that the therapeutic ratio including target coverage & sparing of OARs can be significantly improved, if radiation dose is prescribed to a 3D image-based CTV taking into account dose volume constraints for OARs
- However, prospective use of these recommendations in the clinical context is warranted, to further explore & develop the potential of 3D image-based cervix cancer brachytherapy